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ABSTRACT
OBJECTIVE
To describe the prevalence and clinical spectrum of 
microcephaly in South America for the period 2005-
14, before the start of the Zika epidemic in 2015, as a 
baseline for future surveillance as the Zika epidemic 
spreads and as other infectious causes may emerge 
in future.
DESIGN
Prevalence and case-control study.
DATA SOURCES
ECLAMC (Latin American Collaborative Study of 
Congenital Malformations) database derived from 
107 hospitals in 10 South American countries, 2005 
to 2014. Data on microcephaly cases, four non-
malformed controls per case, and all hospital births 
(all births for hospital based prevalence, resident 
within municipality for population based prevalence). 
For 2010-14, head circumference data were available 
and compared with Intergrowth charts.
RESULTS
552 microcephaly cases were registered, giving a 
hospital based prevalence of 4.4 (95% confidence 
interval 4.1 to 4.9) per 10 000 births and a population 
based prevalence of 3.0 (2.7 to 3.4) per 10 000. 
Prevalence varied significantly between countries 
and between regions and hospitals within countries. 
Thirty two per cent (n=175) of cases were prenatally 
diagnosed; 29% (n=159) were perinatal deaths. 
Twenty three per cent (n=128) were associated 
with a diagnosed genetic syndrome, 34% (n=189) 
polymalformed without a syndrome diagnosis, 12% 
(n=65) with associated neural malformations, and 
26% (n=145) microcephaly only. In addition, 3.8% 
(n=21) had a STORCH (syphilis, toxoplasmosis, 
other including HIV, rubella, cytomegalovirus, and 
herpes simplex) infection diagnosis and 2.0% (n=11) 
had consanguineous parents. Head circumference 
measurements available for 184/235 cases in 2010-
14 showed 45% (n=82) more than 3 SD below the 
mean, 24% (n=44) between 3 SD and 2 SD below the 
mean, and 32% (n=58) larger than −2 SD.
CONCLUSION
Extrapolated to the nearly 7 million annual births 
in South America, an estimated 2000-2500 
microcephaly cases were diagnosed among births 
each year before the Zika epidemic began in 2015. 
Clinicians are using more than simple metrics to make 
microcephaly diagnoses. Endemic infections are 
important enduring causes of microcephaly.
Introduction
After an increase in the number of babies born with 
congenital microcephaly was observed in northeast 
Brazil in 2015 and French Polynesia in 2013-14 
following epidemics of the Zika flavivirus in these 
populations,1 2 the World Health Organization declared 
a public health emergency of international concern 
(now no longer in force) as further global spread of 
the virus was predicted.3 The aim of a diagnosis of 
microcephaly at birth is to use small head circumference 
as an indicator of a high risk of having experienced 
poor in utero development of the brain.4 Microcephaly 
is known to be caused by viral, bacterial, and parasitic 
infections such as rubella, cytomegalovirus, herpes 
simplex virus, immunodeficiency virus, toxoplasmosis, 
and syphilis among others5-9 (as well as many non-
infectious causes), so that an infectious cause of the 
observed increase in affected babies was plausible. 
Since then, more evidence has been accumulating to 
support a causal link,10 11 including the neurotropic 
nature of the Zika virus and preliminary reports of 
epidemiological controlled studies.12-14 However, the 
size of the risk for infected pregnant women remains 
unclear, and the extent of the estimated increase in 
microcephaly in northeast Brazil has not yet been 
observed in other populations affected by Zika.
Infection with the Zika virus in pregnancy has also 
been reported with other brain anomalies, ocular 
manifestations, arthrogryposis, and intrauterine 
growth retardation in the newborn.13 15-18 These 
observations are leading to a broader definition of 
“congenital Zika syndrome”19-28 in a similar way to 
the well established congenital rubella syndrome.29 
Zika may cause a wider spectrum of abnormalities of 
the brain,13 30 which may be diagnosed only later in 
infancy or childhood. Microcephaly itself may become 
manifest later owing to restricted postnatal head 
growth.15
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WhAT IS AlReAdy knoWn on ThIS TopIC
A surge in microcephaly was detected in Brazil at the end of 2015 followed 
by other South American countries as the Zika virus spread throughout the 
continent
However, inconsistent definition and registration of this congenital anomaly 
clouded estimation of the magnitude of increase due to Zika virus
WhAT ThIS STudy AddS
This study provides baseline prevalence for microcephaly in 10 South American 
countries in the pre-Zika period, with which prevalence during the Zika epidemic 
can be compared
The role of other infectious and non-infectious causes should not be ignored 
even in times of Zika epidemic
These data can assist both researchers and governments in coping with the Zika 
induced microcephaly problem
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The definition of microcephaly is not uniform in the 
medical literature.4 Birth defect surveillance systems in 
Europe and the United States have noted registration to 
be poorly standardised,31 32 probably owing to the lack 
of an agreed definition.4 The “metric” microcephaly 
definition (how small a head size is considered 
microcephalic) has changed several times in response 
to the Zika epidemic.33
ECLAMC (Latin American Collaborative Study of 
Congenital Malformations) is a case-control, hospital 
based congenital anomaly surveillance system in 
Latin America (Central and South America), which has 
been operating since 1967.34 Here, we describe the 
prevalence and clinical spectrum of microcephaly in 
South America for the period 2005-14, before the start 
of the Zika epidemic in 2015, as a baseline for future 
surveillance as the Zika epidemic spreads and as other 
infectious causes may emerge in future.
Methods
Description of population and ECLAMC data
Between 2005 and 2014, 107 hospitals (fig 1 and 
supplementary table) belonging to the ECLAMC 
network in 10 South American countries (Argentina, 
Bolivia, Brazil, Chile, Colombia, Ecuador, Paraguay, 
Peru, Uruguay, and Venezuela) registered congenital 
anomalies in a total of 1 247 185 births. Data from 
Central America were not available for this period in 
ECLAMC. The study period predates the Zika epidemic, 
which started in 2015. During the 2005-14 period, 
participation in the ECLAMC network declined, so 
that 46 of the 107 hospitals were participating by 
2010. Fifty seven of the hospitals were university 
hospitals (supplementary table), and there were 
also some non-university tertiary referral hospitals. 
Tertiary hospitals typically serve the local area while 
also receiving referrals of high risk pregnancies and 
pregnancies in which malformations have been 
diagnosed prenatally.
All babies, live and stillborn, with congenital 
anomalies are registered. Termination of pregnancy 
for fetal anomaly was illegal during the study period 
(until 2014) in all countries, except under certain very 
restricted conditions that would not be specifically 
relevant to microcephaly.
In each hospital, the paediatrician diagnoses the 
congenital anomalies and enters the data by choosing 
the diagnosis from an electronic list, which is coded 
automatically to ICD-8 (international classification 
of disease, version 8) codes with a two digit ECLAMC 
extension for further specification and laterality. This 
information is transmitted to the ECLAMC central 
database. All diagnostic information is collected from 
the maternity unit up to but not beyond discharge.
For each malformed baby born in the hospital, a 
liveborn non-malformed control is chosen as the 
next birth of the same sex in the same hospital. If 
the next birth is not available, the subsequent birth 
is selected (17.5% of controls). The participation 
rate in ECLAMC hospitals by mothers of both cases 
and controls is very high. The mothers of both 
cases and controls are interviewed by the ECLAMC 
paediatrician (usually) or by a designated nurse or 
medical student, depending on hospital, before they 
are discharged from the maternity unit, according to 
a standard interview schedule described elsewhere.34 
A data entry programme is accessed via a secure 
internet portal to the ECLAMC server. Before 2010 
data entry was by palm held device and transmitted 
electronically.
The information collected from medical records 
for the malformed baby includes the diagnosis, 
whether the malformation was diagnosed prenatally, 
gestational age, and birth weight. The information 
collected from maternal interviews and analysed 
in this paper includes consanguinity (up to 
second cousin), exposure to STORCH (syphilis, 
toxoplasmosis, other including HIV, rubella, 
cytomegalovirus, and herpes simplex), influenza, 
diabetes, and demographic information such as 
residence of the mother, maternal age, and maternal 
education. Death in the first three days (by the time 
of data collection) was recorded. “Perinatal deaths” 
as used in this paper is the addition of stillbirths and 
deaths in the first three days of life. Each hospital 
Non-university hospitals
University hospitals
Fig 1 | Map of 107 hospitals in ECLAMC 2005-14. Hospital 
codes are given in supplementary table
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collects a limited set of data on all births delivered in 
the hospital, including the total number of live births 
and stillbirths for calculation of prevalence.
Definition and classification of microcephaly
The ECLAMC operational manual defines microcephaly 
(ICD-8 code 743.1) as head circumference more than 
3 SD below the mean (−3 SD) for gestational age 
and sex; any other criteria used instead by hospitals 
should be specified as part of the diagnostic text. 
The ECLAMC manual does not specify the growth 
chart to be used by hospitals, and nor has this been 
specified in the diagnostic text given by paediatricians. 
ECLAMC protocols are reinforced by annual meetings 
of ECLAMC paediatricians, but the specific question 
of standardisation of the definition and diagnosis 
of microcephaly did not come up during the study 
period. This paper includes any diagnosis of 
microcephaly made by paediatricians, whether or not 
its diagnosis follows the ECLAMC head circumference 
recommendation.
Head circumference data are requested to be added 
to the ECLAMC data for any baby with microcephaly, 
collected as additional text, but these data were 
accessible for analysis only from 2010 when data 
entry was by internet portal. For the purposes 
of this research, we converted all available head 
circumference data from 2010 on, when gestational 
age and sex had also been specified, to z scores 
(specific to gestational age and sex) according to the 
Intergrowth charts for very preterm and preterm/term 
babies by using the International Standards for Size at 
Birth app (v1.0.5934.26288).35 As gestational age is 
recorded in completed weeks, we used the Intergrowth 
modelled estimates for each gestational week+3 days. 
The slight discontinuity in the Intergrowth models 
for very preterm and preterm/term babies giving a 
higher growth rate at 33 weeks was not smoothed. 
Birth weight was also classified to z scores by the same 
Intergrowth charts for 2005-14.
A clinical geneticist (IMO), working centrally on the 
basis of the diagnostic codes and text descriptions 
given by the hospital paediatrician (syndromes were 
diagnosed by the paediatricians, not centrally), 
further classified microcephaly cases as follows. (A) 
Syndromes—A1 genetic syndromes (A1.1 chromosomal 
and A1.2 monogenic syndromes); A2—embryopathies 
(teratogenic/environmental syndromes). (B) 
Polymalformed microcephaly—microcephaly with 
other major non-neural malformations excluding A. 
(C) Microcephaly with associated malformations of 
neural origin (brain, spinal cord, ocular) excluding 
cases classified to A or B. (D) Isolated microcephaly—
only microcephaly coded, or microcephaly with minor 
additional anomalies.
Categories C and D, with the addition of cases from 
category A in which no major non-neural associated 
anomalies existed (shown in the last column of table 1), 
were further analysed together as “neural only cases.” 
Analysis of “neural only cases,” similar to microcephaly 
now associated with Zika,22 would show the frequency 
of causative factors associated with such a phenotype 
in a non-Zika period. However, genetic syndromes or 
embryopathies (category A) may be underrepresented 
as they include only those diagnosed in the first few 
days of life (some microcephaly cases may have 
received syndrome diagnoses later than this). All cases 
and controls with STORCH infections had laboratory 
confirmed evidence of infection. Cases had in addition 
a STORCH embryopathy diagnosis (classified to A2 
above) given by the paediatrician at the hospital. Some 
brain imaging and genetic syndrome diagnoses for 
microcephaly cases may be missing if they became 
available after discharge from the maternity unit. We 
specifically analysed the presence of arthrogryposis, 
as it is emerging as part of the definition of congenital 
Zika syndrome.17 18
Statistical analysis
We calculated prevalence of microcephaly as the 
number of cases of microcephaly (live and stillborn) 
divided by the total number of births, and expressed 
it per 10 000 births.36 We calculated two estimates for 
regions and countries—a hospital based estimate and a 
population based estimate. The hospital based estimate 
included all cases born in the participating hospitals, 
with a denominator of all births in the participating 
hospitals. As some of the participating hospitals are 
tertiary centres that attract high risk pregnancies or 
prenatally diagnosed cases, the population based 
estimate included only babies with microcephaly to 
residents of the same municipality as the hospital, 
with a denominator estimated as the number of births 
multiplied by the proportion of controls (controls of all 
malformed babies in the same year) who were resident 
in the same municipality as the hospital.
We used a multilevel Poisson random effects model 
to analyse secular trend in prevalence. Prevalence by 
region and country are shown with Poisson exact 95% 
confidence intervals. We analysed case-control data by 
conditional logistic regression with matching variables 
of year, hospital, and sex. For this study, to improve 
statistical power, we used the microcephaly matched 
control as well as the three subsequent non-malformed 
controls chosen for babies with other malformations in 
the same hospital and year and of the same sex. Odds 
ratios were adjusted for maternal age and maternal 
education. We analysed odds ratios for all microcephaly 
cases and for all neural only cases. We used Stata 12 
statistical software for all analyses. The sample size of 
the primary case-control study allows identification of 
a twofold risk factor for an exposure frequency of 5% 
with a test power of 70% and a significance level of 
5%, or an odds ratio greater than 4 with a risk factor 
prevalence of 1%.
Extrapolation to South America
We extrapolated our prevalence results to all 6.8 
million births in South America (2016 estimate 
from www.worldpopdata.org), using both a simple 
estimate (the population based prevalence applied to 
all births in South America) and a country stratified 
RESEARCH
4 doi: 10.1136/bmj.j5018 | BMJ 2017;359:j5018 | the bmj
estimate (the country specific, population based 
prevalence applied to each participating country’s 
annual births).
Patient involvement
No patients were involved in setting the research 
question or the outcome measures, nor were they 
involved in developing plans for recruitment, design, 
or implementation of the study. No patients were asked 
to advise on interpretation or writing up of results. 
There are no plans to disseminate the results of the 




Five hundred and fifty two cases of microcephaly 
were recorded, a hospital based prevalence of 4.4 
(95% confidence interval 4.1 to 4.9) per 10 000 
births, including live births and stillbirths. Hospital 
Table 1 | Clinical classification of microcephaly cases. Values are numbers (percentages) unless stated otherwise
Clinical classification










Neural only  
cases
A1.1. Chromosomal syndromes: 68 (12.3) 0.55 0.51 30 (44) 52 (76) 0
 Patau 41
 Edwards 14
 Other chromosomal anomaly 8
 Down 3
 Turner 1
 5p- deletion 1
A1.2. Monogenic syndromes: 60 (10.9) 0.48 0.78 29 (48) 22 (37) 2 (3)
 Holoprosencephaly† 36
 Meckel 5
 Skeletal dysplasia 3




 Cornelia de Lange 1
 Treacher Collins 1
 Freeman-Sheldon 1
 Acrocallosal 1
 Dominant lissencephaly 1
 Ivemark 1
A2. Embryopathies: 25 (4.5) 0.20 0.67 4 (16) 3 (12) 18 (72)
 Embryopathy cytomegalovirus‡ 9
 Embryopathy toxoplasmosis‡ 4
 Brain disruption with dead twin 2
 Embryopathy alcohol 2
 Embryopathy syphilis‡ 2
 Embryopathy rubella‡ 2
 Embryopathy HIV+syphilis‡ 1
 Embryopathy HIV+toxoplasmosis‡ 1
 Embryopathy syphilis+toxoplasmosis‡ 1
 Embryopathy rubella+syphilis‡ 1
B. Polymalformed without syndrome diagnosis 189 (34.2) 1.52 0.89 63 (33) 67 (35) 0
C. Microcephaly with associated malformations 
of neural origin:
65 (11.8) 0.52 0.91 31 (48) 5 (8) 65 (100)
 Encephalocele 13
 Brain necrosis/calcification 9
 Hydrocephaly with calcifications, neuronal  
migration, or other brain anomalies
9
 Neuronal migration abnormality 7
 Corpus callosum anomaly 5
 Spina bifida 4
 Cerebellar anomaly 4
 Hydrocephaly 4
 Hydranencephaly 4
 Other brain defects 4
 An/cryptophthalmos 1
 Corneal opacity 1
D. Isolated microcephaly 145 (26.3) 1.16 0.56 18 (12) 10 (7) 145 (100)
Total microcephaly cases 552 (100.0) 4.43 0.72 175 (31.7) 159 (28.8) 230 (41.7)
*Stillbirths and deaths in the first three days of life.
†All holoprosencephaly without chromosomal syndrome or embryopathy were attributed to monogenic category whether or not monogenic, digenic, or copy number variation syndrome diagnosis 
was made.
‡STORCH (syphilis, toxoplasmosis, other including HIV, rubella, cytomegalovirus, and herpes simplex) embryopathies: six STORCH cases had other major congenital anomalies, four of which were 
heart defects.
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based prevalence varied by country and by region 
(table 2). Variation between hospitals was significant 
(χ2=950.5, df=106; P<0.001) and is shown in fig 2 
for 56 hospitals with at least 5000 births. Seventy 
one per cent (22 408/31 560) of controls and 
49% (268/552) of cases were resident within the 
municipality of the hospital. The population based 
prevalence estimate was 3.0 (2.7 to 3.4) per 10 000 
births. Population based prevalence also varied by 
country and region (table 2). The highest prevalence 
was recorded in Brazil, specifically northeast and 
southeast Brazil, but the region of metropolitan Chile 
also recorded a high prevalence (table 2). One of the 
hospitals in Rio de Janeiro (southeast Brazil, hospital 
code A05; supplementary table) is a highly selective 
tertiary centre in the Rio municipality with an overall 
malformation rate of 22%. The population based 
prevalence for Rio (see footnote to table 2) remains 
high, as Rio is a single municipality and there is further 
selection within municipality that cannot be corrected 
for; this explains some of the high prevalence in 
southeast Brazil. We found no significant secular trend 
in prevalence (prevalence rate ratio: linear term 0.99, 
95% confidence interval 0.95 to 1.02; quadratic term 
0.99, 0.98 to 1.00).
The live birth hospital based prevalence of 
microcephaly (as a proportion of all live births) was 
4.5 (3.9 to 4.9) per 10 000; 1.2% of all births were 
stillbirths, and as a proportion of all stillbirths the 
microcephaly prevalence was higher at 17.5 (16.9 
to 18.1) per 10 000. Overall, “perinatal mortality” 
was 29% among all microcephaly cases and 7% 
among neural only cases (table 3). Microcephaly or 
an associated congenital anomaly was prenatally 
diagnosed in 32% of all cases or 22% of neural only 
cases (table 3).
Table 2 | Prevalence of microcephaly by country and region, 2005-14
Country and region (No of hospitals)
Hospital based Population based
Cases Total births
Prevalence, per  
10 000 (95% CI) Cases Births
Prevalence, per  
10 000 (95% CI)
Argentina (35): 95 316 771 3.0 (2.4 to 3.7) 39 237 702 1.6 (1.2 to 2.2)
 Buenos Aires (9) 17 53 032 3.2 (1.8 to 5.1) 4 43 420 0.92 (0.25 to 2.4)
 Centro (2) 13 33 768 3.8 (2.1 to 6.6) 6 27 793 2.2 (0.79 to 4.7)
 Cuyo (5) 3 31 566 1.0 (0.20 to 2.8) 2 26 609 0.75 (0.09 to 2.7)
 Nordeste (1) 2 17 096 1.2 (0.14 to 4.2) 2 17 096 1.2 (0.14 to 4.2)
 Noroeste (4) 36 92 936 3.9 (2.7 to 5.4) 6 45 718 1.3 (0.48 to 2.9)
 Pampa (9) 23 80 233 2.9 (1.8 to 4.3) 18 68 926 2.6 (1.6 to 4.1)
 Patagonia (5) 1 8140 1.2 (0.03 to 6.8) 1 8140 1.2 (0.03 to 6.8)
Bolivia (5): 18 80 322 2.2 (1.3 to 3.5) 11 58 080 1.9 (0.95 to 3.4)
 Andes (4) 14 52 372 2.7 (1.5 to 4.5) 9 40 520 2.2 (1.0 to 4.2)
 Subandina (1) 4 27 950 1.4 (0.4 to 3.7) 2 17 560 1.1 (0.14 to 4.1)
Brazil (22): 251 303 922 8.3 (7.3 to 9.4) 114 209 834 5.4 (4.5 to 6.5)
 Centro (1) 1 3997 2.5 (0.06 to 13.9) 1 3854 2.6 (0.07 to 14.5)
 Nordeste (4) 76 90 891 8.4 (6.6 to 10.5) 34 49 501 6.9 (4.8 to 9.6)
 Sudeste (11) 144 88 052 16.4* (13.8 to 19.3) 70 68 178 10.3 (8 to 12.9)
 Sul (6) 30 120 982 2.5 (1.7 to 3.5) 9 88 301 1.0 (0.47 to 1.9)
Chile (11): 89 192 401 4.6 (3.7 to 5.7) 43 102 631 4.2 (3.0 to 5.6)
 Lagos (1) 7 34 665 2.0 (0.81 to 4.2) 5 23 229 2.2 (0.70 to 5.0)
 Maule (4) 19 91 244 2.1 (1.3 to 3.3) 12 49 915 2.4 (1.2 to 4.2)
 Metropolitana (6) 63 66 492 9.5 (7.3 to 12.1) 26 29 487 8.8 (5.8 to 12.9)
Colombia (15): 53 152 485 3.5 (2.6 to 4.6) 41 122 437 3.3 (2.4 to 4.5)
 Caribe (1) 2 1411 14.2 (1.7 to 51.2) 1 1411 7.1 (0.18 to 39.5)
 Sabana (12) 40 83 693 4.8 (3.4 to 6.5) 34 69 115 4.9 (3.4 to 6.9)
 Valle (2) 11 67 381 1.6 (0.8 to 2.9) 6 51 911 1.2 (0.4 to 2.5)
Ecuador (11): 23 81 835 2.8 (1.8 to 4.2) 10 63 085 1.6 (0.76 to 2.9)
 Costa (4) 2 19 484 1.0 (0.1 to 3.7) 0 16 666 0 (0 to 2.2)
 Sierra (7) 21 62 351 3.4 (2.1 to 5.2) 10 46 419 2.2 (1.0 to 3.9)
Paraguay (1): 1 5237 1.9 (0.05 to 10.6) 0 1885 0 (0 to 19.6)
 Asuncion (1) 1 5237 1.9 (0.05 to 10.6) 0 1885 0 (0 to 19.6)
Peru (1): 6 19 881 3.0 (1.1 to 6.6) 6 19 881 3.0 (1.1 to 6.6)
 Lima (1) 6 19 881 3.0 (1.1 to 6.6) 6 19 881 3.0 (1.1 to 6.6)
Uruguay (2): 0 9553 0 (0 to 3.9) 0 9553 0 (0 to 3.9)
 Maldonado (1) 0 1922 0 0 1922 0
 Montevideo (1) 0 7631 0 0 7631 0
Venezuela (4): 16 84 778 1.9 (1.1 to 3.1) 4 55 986 0.71 (0.19 to 1.8)
 Guyana (1) 1 9868 1.0 (0.03 to 5.7) 1 9868 1.0 (0.03 to 5.7)
 Occidente (1) 13 54317 2.4 (1.3 to 4.1) 2 25 525 0.78 (0.09 to 2.8)
 Zulia (2) 2 20593 1.0 (0.12 to 3.5) 1 20 593 0.49 (0.01 to 2.7)
All countries (107) 552 1 247 185 4.4* (4.1 to 4.9) 268 881 074† 3.0 (2.7 to 3.4)
*Removal of high prevalence tertiary A05 hospital from Brazil gives estimated hospital based prevalence for Brazil SE of 9.6/10 000 (95% CI 7.5 to 11.9; n=75; births=78 470) and all 
countries prevalence of 3.9/10 000 (3.6 to 4.3; n=483; births=1 237 603). A05 alone has hospital based prevalence of 72/10 000 (56.1 to 91; n=69; births=9582) and population based 
prevalence of 52.4/10 000 (36.3 to 76.1). Brazil SE population based prevalence without A05 is 2.7/10 000 (2.3 to 3.0).
†Estimated from 71% of controls residing within municipality of hospital (0.71*1 247 187=881 074).
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Extrapolated to the 6.8 million births in South 
America, we estimate that the number of microcephaly 
cases being born per year before Zika was between 
2058 (simple estimate) and 2465 (stratified estimate, 
substituting South American average prevalence for 
the two countries with zero cases in table 2).
Clinical and phenotypic spectrum
Table 1 shows the distribution of clinical classification 
(2005-14). Twenty three per cent or 1.0 per 
10 000 births were genetic syndromes, 5% were 
embryopathies, 34% were polymalformed, 12% were 
microcephaly with associated neural conditions, and 
26% were coded only as microcephaly; 230 cases 
(42% of all cases) were neural only cases (table 1). 
The sex ratio was significantly skewed towards females 
(tables 1 and 3).
Fifty four per cent of microcephaly cases were low 
birth weight (<2500 g) (table 3); 27% of microcephaly 
cases had a birth weight lighter than 2 SD below the 
mean (−2 SD), including 7% with a birth weight lighter 
than −3 SD (table 3). For the 2010-14 period cases, 
45% of head circumferences were less than −3 SD 
and 24% were between −3 and −2 SD. On inspection 
of 41/58 cases with head sizes larger than −2 SD, 
eight (19%) had hydrocephaly, seven (17%) had 
spina bifida, two (5%) had lissencephaly, and seven 
(17%) had other cerebral defects; other conditions (2 
(1%)) were mentioned in which brain size might not 
be reflected in head size, such as head deformity and 
loose/redundant skin over the head, and others were 
unexplained. Of the 126 cases with a head size smaller 
than −2 SD, 47 (37%) also had a birth weight smaller 
than −2 SD. The equivalent figure for −3 SD was 82 
cases, of which 10 (12%) also had a birthweight 
smaller than −3 SD.
Parental consanguinity was present in 2% (n=11) 
of all cases and 0.7% of controls (table 4). Four of the 
consanguineous cases had been diagnosed as having 
genetic syndromes (category A), but consanguinity 
was also present in seven isolated (category D) 
cases with no diagnosed genetic syndrome, of which 
five were first cousins. The association between 
consanguinity and neural only microcephaly was 
strong (odds ratio 3.1, 95% confidence interval 1.4 
to 7.0) (table 4).
STORCH embryopathies were diagnosed in 3.8% of 
total cases (table 1), with an odds ratio of 4.4 (2.3 to 
8.4) (table 4). Of the 21 STORCH microcephaly cases, 
15 were neural only cases (7% of all neural only cases) 
and six had other congenital anomalies (table 1).
The polymalformed cases included 13 with 
microcephaly and arthrogryposis, all of which also had 
other malformations of non-neural origin. There were 
no cases of microcephaly and arthrogryposis that did 
not also have non-neural origin anomalies.
Sociodemographic risk factors
For all cases and neural only cases, we found no 
association with older maternal age or low maternal 
education (table 4).
Argentina, Buenos Aires (317)
Argentina, Buenos Aires (318)
Argentina, Buenos Aires (322)
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Fig 2 | Forest plot of hospital based prevalence per hospital (country, region), 
2005-14, showing only 55 hospitals with ≥5000 births. Hospital codes are given 
in supplementary table. Hospital A05 not shown as off scale: hospital based 
prevalence=72/10 000 (95% CI 56.1 to 91.0; n=69, births=9582)
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discussion
Before the Zika epidemic, the average hospital 
based  prevalence of microcephaly recorded by 
ECLAMC in South America for the 2005-14 period 
was 4.4 per 10 000 births, and the estimated 
population based prevalence was 3.0 per 10 000. 
Prevalence varied considerably by country, region, 
and hospital. As selective referral of prenatally 
diagnosed cases of congenital anomaly or high 
risk pregnancies to tertiary hospitals may occur, 
the prevalence in single hospitals may be inflated 
compared with the population as a whole. We 
estimate the average population based prevalence 
to be 31% less than the hospital based prevalence 
and recommend that Zika related surveillance 
takes hospital selection into account and provides 
population based prevalence. However, we found 
that hospital selection explained little of the 
geographical variation in prevalence of diagnosed 
cases—substantial geographical variation remained 
in population based prevalence. On the basis of this 
prevalence of 3.0 per 10 000, we estimate that 2000 
to 2500 babies were being diagnosed as having 
microcephaly each year before the Zika epidemic, 
among the nearly 7 million annual births in South 
America.
Comparison with other studies
Previous estimates of the prevalence of microcephaly 
in South America and elsewhere have been within 
a similar range. ECLAMC data showed an average 
hospital based prevalence of 3.7/10 000 for 1982-
2008, ranging from 2.1 in Venezuela to 5.1 in Brazil 
and 5.5 in Chile.37 Other studies in South America that 
overlap to a small extent with ECLAMC data reported 
a population based prevalence of 3.1/10 000 in the 
region of Risaralda, Colombia, in 2010-13 and a 
hospital based prevalence of 2.4/10 000 in Argentina 
in 2010-14.38 39 In Europe in 2003-12, a population 
based prevalence of 1.5/10 000, excluding 23% with 
genetic syndromes, was recorded,31 and a hospital 
based prevalence of 2.3/10 000 was reported in 
India from 1963 to 1995.40 The pooled prevalence 
of microcephaly among the United States population 
based surveillance systems was higher at 8.7 per 
10 000 from 2009 to 2013.32 Both European and 
US surveillance systems documented considerable 
geographical variation, which was due at least in part 
to diagnostic variability.
Implications for diagnosis of microcephaly
The ECLAMC surveillance data, like data from other 
surveillance systems,31 32 records diagnoses made by 
clinicians for clinical (not research) purposes, which 
are only to a limited extent subject to standardisation 
by belonging to a surveillance network. In our data, 
about half of cases had a head size larger than −3 SD 
(according to the Intergrowth curve), including some 
larger than −2 SD in whom other signs indicated an 
abnormally small brain. This is despite the ECLAMC 
recommendation to use a threshold of −3 SD. Some 
of this discrepancy may relate to differences between 
the growth charts used (Intergrowth charts were 
not widely used in this period) and whether they 
explicitly show the −3 SD threshold measurements. 
Most readily available charts, including Intergrowth, 
showed only the third centile during this period,35 41-43 
the third centile being equivalent to the lowest 3% of 
measurements of the reference population compared 
with 2.3% for −2 SD and 0.13% for −3 SD in a normal 
distribution (https://www.zscorecalculator.com/). 
It also follows that use of other charts might have 
meant that clinicians missed cases that would be 
microcephalic by the Intergrowth chart. A US analysis 
of surveillance data found that 42% of microcephaly 
cases had head circumference larger than the 10th 
centile (the lowest 10%, equivalent to −1.3 SD) by 
the Intergrowth curve, an even greater proportion of 
large head circumferences than we found in South 
America.32
Our data, the literature,4 31 32 45 46 and discussions 
with paediatricians suggest that clinical judgment goes 
beyond a simple metric microcephaly. Paediatricians 
do (and should) use other signs as well as head 
circumference at birth to determine which baby has a 
small brain and whether this is likely to be associated 
with brain pathology and poor neurodevelopmental 
outcome. Head circumference is only a screening 
Table 3 | Description of all microcephaly cases and neural only cases*. Values are 
numbers (percentages)
Characteristic
All microcephaly  
cases (n=552)
Neural only  
cases (n=230)
Live born 525 (95.1) 229 (>99)
Stillborn 25 (4.5) 1 (0.4)
All perinatal deaths 159 (28.8) 17 (7)
Male 227 (41.1) 92 (40)
Female 315 (57.1) 138 (60)
Intersex 8 (1.4) 0
Twin 14 (2.5) 8 (3)
Prenatally diagnosed 175 (31.7) 51 (22)
Preterm (<37 weeks) 195 (35.3) 51 (22)
Term not specified 32 (5.8) 17 (7)
Low birth weight (<2500 g) 296 (53.6) 94 (41)
Birth weight z score not calculated 46 (8.3) 29 (13)
Birth weight <−2 SD 134/506 (26.5) 40/201 (20)
Birth weight <−3 SD 33/506 (6.5) 7/201 (3)
2010-14 only
All data: 235 (42.6) 95 (41)
 HC z score not calculated† 51/235 (22) 8/95 (8)
 HC<−3 SD 82/184 (45) 38/87 (44)
 −2 SD≤HC≥−3 SD 44/184 (24) 27/87 (31)
 −1 SD≤HC>−2 SD 37/184 (20) 18/87 (21)
 HC>−1 SD 21/184 (11) 4/87 (5)
Preterm: 55/184 (30) 15/87 (17)
 HC<−3 SD 21/55 (38) 8/15 (53)
 −2 SD≤HC≥−3 SD 8/55 (15) 2/15 (13)
 −1SD≤HC>−2 SD 14/55 (25) 4/15 (27)
 HC>−1 SD 12/55 (22) 1/15 (7)
Term: 129/184 (70) 72/87 (83)
 HC<−3 SD 61/129 (47) 30/72 (42)
 −2 SD≤HC≥−3 SD 36/129 (28) 25/72 (35)
 −1 SD≤HC>−2 SD 23/129 (18) 14/72 (20)
 HC>−1 SD 9/129 (7) 3/72 (4)
*Two cases were unspecified as to whether live born or stillborn and for sex.
†z score not calculated as sex not specified (2), intersex (4), gestational age not specified (1), gestational age 
outside Intergrowth range (24-42 weeks+6 days) (8), or head circumference not specified (43).
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tool, but it may have assumed a status as a sole metric 
diagnostic arbiter in textbook definitions. Other signs 
that improve the predictive value may include slowing 
growth rate of the head in utero and postnatally, 
presence of associated major or minor malformations 
(59% of our larger head size cases had neural 
anomalies that suggested small brain size) or abnormal 
facies suggesting teratogenic factors, exposure to 
known risk factors (of which Zika may become one), 
proportionality of head size to body size,47 parental 
head size, brain imaging results,14 15 48-50 52 and any 
abnormalities of head shape that invalidate judgments 
made about occipitofrontal head circumference such 
as head moulding or water loss.53-55
Some under-ascertainment of microcephaly in 
ECLAMC and other surveillance systems is also 
possible. When the underlying or an associated 
pathology is known and diagnosed—for example, a 
specific syndrome or specific brain malformation—
microcephaly may not always be specified as a 
supplementary diagnosis.
The WHO has recommended in response to the Zika 
epidemic that microcephaly should be defined as head 
circumference below −2 SD,51 rather than −3 SD as 
used by congenital anomaly surveillance systems,31 32 
particularly as not all Zika affected babies have heads 
smaller than −3 SD.14 21 50 As a definition of −2 SD on 
its own has the disadvantage of low specificity,50 and 
unnecessary anxiety, giving many babies with normal 
brains a microcephaly diagnosis,22 46 and leading to 
a huge potential increase in recorded microcephaly 
prevalence compared with previous levels, both the 
Brazilian microcephaly monitoring and the WHO 
surveillance manual have recommended that a 
diagnosis of microcephaly should be confirmed at 
this level for congenital Zika surveillance only if other 
evidence of structural abnormalities exists.33 51 The 
implementation of this definition may lead to a certain 
amount of standardisation in future but leave several 
areas of potential variability as discussed above. What 
is clear is that purely “metric microcephaly” is not a 
viable definition of a clinical entity, even when restricted 
to −3 SD, and also that an alert such as Zika has the 
potential to lead to large artefactual increases in the 
prevalence of diagnosed microcephaly. Microcephaly 
surveillance should move beyond measurement based 
definition to a pathology based definition.
Potential explanations and implications
In the period 2005-14 before Zika, the highest 
microcephaly prevalences in our data were already 
recorded in Brazil, especially southeast and northeast 
Brazil, where later (from 2015 on) the Zika epidemic 
and microcephaly surge began, but a high prevalence 
was also observed in metropolitan Chile. We have 
no explanation for this or more generally for the 
geographic variation observed—a vulnerability to or 
higher background frequency of teratogenic exposures, 
or diagnostic factors as discussed above, or both could 
be hypothesised.
Table 4 | Potential risk factors for microcephaly: number (percentage) exposed for cases and controls, and odds ratio adjusted for maternal age and 
education (95% CI)
Exposure











Adjusted odds  
ratio (95% CI)
Maternal age:
 <20 years 104 (19.0) 444 (20.4) 0.81 (0.62 to 1.0) 49 (21) 209 (22.8) 0.77 (0.53 to 1.1)
 20-34 years 360 (65.9) 1263 (58.0) 1.0 156 (68) 547 (59.7) 1.0
 ≥35 years 82 (15.0) 241 (11.1) 1.2 (0.88 to 1.6) 25 (11) 97 (10.6) 0.84 (0.51 to 1.4)
 Not specified 0 228 (10.5) – 0 64 (7.0) –
Maternal education:
 <6 years 111 (20.3) 345 (15.9) 1.2 (0.92 to 1.6) 37 (16) 147 (16.0) 1.0 (0.64 to 1.5)
 6-12 years 358 (65.6) 1364 (62.7) 1.0 161 (70) 597 (65.1) 1.0
 ≥13 years 55 (10.1) 186 (8.5) 1.1 (0.77 to 1.5) 25 (11) 91 (9.9) 1.0 (0.59 to 1.6)
 Not specified 22 (4.0) 281 (12.9) – 7 (3) 82 (8.9) –
Consanguinity:
 Yes 11 (2.0) 15 (0.7) 3.1 (1.4 to 7.0) 7 (3) 10 (1.1) 3.1 (1.1 to 8.9)
 No 535 (98.0) 1865 (85.7) 1.0 216 (94) 818 (89.2) 1.0
 Not specified 0 296 (13.6) – 7 (3) 89 (9.7) –
STORCH:
 Yes 21 (3.8) 21 (1.0) 4.4 (2.3 to 8.3) 15 (7) 15 (1.6) 6.3 (2.6 to 15.1)
 No 525 (96.2) 2155 (99.0) 1.0 215 (93) 902 (98.4) 1.0
 Not specified 0 0 – 0 0 –
Diabetes:
 Yes 13 (2.4) 52 (2.4) 1.0 (0.53 to 1.9) 5 (2) 5 (0.5) 1.0 (0.38 to 2.9)
 No 533 (97.6) 2124 (97.6) 1.0 225 (98) 912 (99.5) 1.0
 Not specified 0 0 – 0 0 –
Influenza:
 Yes 26 (4.8) 57 (2.6) 1.9 (1.1 to 3.3) 12 (5) 12 (1.3) 2.7 (1.8 to 6.4)
 No 520 (95.2) 2119 (97.4) 1.0 218 (95) 905 (98.7) 1.0
 Not specified 0 0 – 0 0 –
STORCH=syphilis, toxoplasmosis, other including HIV, rubella, cytomegalovirus, and herpes simplex.
*Six cases were removed as matched controls could not be identified owing to cases being intersex (4) or having unspecified sex (2).
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The range of abnormalities associated with 
congenital Zika syndrome are still being defined.19-28 
Although initially the recognition of this syndrome 
drove a widening of the microcephaly definition, 
it is now recognised that microcephaly is only one 
of a range of neural abnormalities. We found 2.4% 
(13/552) of cases of microcephaly with arthrogryposis, 
one of the findings relating to Zika,17 18 but these were 
all polymalformed cases that also had other non-neural 
malformations. At least 34 genetic syndromes present 
with congenital microcephaly plus arthrogryposis.56 
Intrauterine growth retardation has been a common 
Zika related finding,13 15 including in animal models.57 58 
We found proportionate microcephaly to account 
for 37% of babies with head size less than −2 SD, 
but for those with head size more than −3 SD it was 
uncommon for birth weight to be proportionately 
reduced. Development of the congenital Zika syndrome 
definition will need to consider carefully whether 
to distinguish proportionate growth retardation 
with normally formed brain from microcephaly 
with evidence of abnormal brain structure, 
including consideration of prognosis in terms of 
neurodevelopmental outcome, which may come from 
the cohort studies now in progress.
Twenty three per cent of our cases had a diagnosed 
genetic syndrome, a prevalence of 1 per 10 000, similar 
to the 23% of genetic cases reported by EUROCAT and 
23% reported in the US,31 32 and it is important that 
differential diagnosis is maintained during epidemic 
periods. Autosomal recessive types of microcephaly, 
well recognised in the microcephaly literature,59 for 
which consanguineous parents would be at higher 
risk, are more difficult to identify at birth as suggested 
by our very high odds ratio for parental consanguinity 
among neural only cases, of which few had been 
diagnosed as having syndromes. As new genetic 
diagnostic methods become more widely available, 
the proportion of genetic syndromes is likely to rise in 
future.
Although Zika is of great relative importance during 
an epidemic, owing to high numbers of exposed non-
immune women, the strong and known associations 
we found with other infections are of continuing 
importance. Current estimates of the rate of affected 
babies after Zika infection in early pregnancy are in 
the order of 1-13%,2 60 61 but infections such as rubella 
are more highly teratogenic (with up to 100% birth 
defects when exposure occurred before the 11th week 
or 35% of those infected between the 13th and 16th 
weeks) but not as specific to neural anomalies.62 We 
found in these pre-Zika data that 4% of microcephaly 
cases (or 7% of neural only cases) were associated 
with STORCH infections, in some cases more than one 
infection. A Colombian surveillance study reported 
that 21% of microcephaly cases tested had evidence 
of STORCH infections.63 The STORCH infections in 
1.5% of our non-malformed controls, some of whom 
may have had later neurodevelopmental problems, 
suggest a significant population level of maternal 
infection during pregnancy, even though this is likely 
to be an underestimate owing to incomplete screening. 
We also found a significant association with reported 
influenza, which has not previously been found in 
the literature,64 that may also indicate fever relating 
to other infectious diseases being interpreted as 
influenza. Zika may be a useful “wake-up call” to the 
effect of infections during pregnancy. Each STORCH 
infection is estimated to be associated with between 
100 000 and more than a million cases of congenital 
infection globally each year.5 65 67
Strengths and limitations of study
A strength of the ECLAMC surveillance system is that 
it uses a common protocol in all countries. However, 
hospitals receive no funding for their participation 
and are not able to follow up cases beyond discharge 
from the maternity unit. This means that some 
brain imaging and genetic syndrome diagnoses for 
microcephaly cases may be missing, and some of the 
polymalformed or isolated cases classified here may 
have later been given syndrome diagnoses. Diagnostic 
data are collected within the healthcare possibilities of 
each hospital, in a “real world” rather than research 
context. This is common to surveillance systems 
worldwide,31 32 which use standardised reporting 
systems for healthcare data that may arise from non-
standardised clinical practice. We found that data were 
missing for some variables, which indicates the need 
for improved reporting in ECLAMC. Mothers may not 
accurately or completely recall information about their 
exposures when interviewed. Our description of head 
circumference of microcephaly cases was limited to 
2010-14 and may not be representative of the earlier 
period (2005-09).
Whereas hospital based surveillance has the 
advantage of ensuring high data quality coming 
from selected participating hospitals, a strength of 
the ECLAMC system, selective referral to tertiary or 
specialist hospitals is problematic for the estimation 
of population based prevalence. As there are often 
multiple hospitals within municipalities, and it 
was not possible to correct for within municipality 
selection, we could not give fully population based 
prevalence estimates, but we believe our population 
based estimates to be an improvement over the hospital 
based estimates for public health surveillance. Our 
extrapolation to the entire population of South America 
is approximate only. All South American countries, 
except Guyana, Suriname, and French Guiana, were 
represented in our data.
Conclusions
We have established a baseline for the prevalence of 
diagnosed microcephaly before the Zika epidemic 
with which the prevalence during and after the Zika 
epidemic can be compared, with strong caveats due 
to the problems of definition. We have also shown 
that, even in non-Zika times, the potential effects of 
infectious and non-infectious causes of abnormal brain 
development should not be ignored. What may set the 
Zika epidemic apart from other endemic infections are 
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the high exposure rate in the population as it sweeps 
through non-immune populations and its specificity to 
neural anomalies.
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